BioCentury
ARTICLE | Company News

Celltech Group deal

October 16, 1995 7:00 AM UTC

The companies will collaborate to develop gelatinase inhibitors to treat cancer. Zeneca has worldwide marketing rights to the resulting technology, while CTP (Slough, U.K.) will receive up to $15.8 million in clinical milestone payments and royalties. ...